Skip to main content
An official website of the United States government

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Trial Status: active

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.